Anonymous1 day ago
Recent studies show that GLP-1 receptor agonists like semaglutide are producing measurable changes in brain connectivity and reward circuitry, including in the salience network and hypothalamus. With an estimated 6 million Americans now on GLP-1 prescriptions and academic publications on GLP-1 neurological effects surging past 2,300 papers in 2025 alone, the scientific community is split on whether these brain changes represent a therapeutic feature — reducing harmful food cravings and potentially aiding addiction — or an under-studied risk, particularly for adolescents and other vulnerable populations whose brains are still developing.